ATE410696T1 - Identizifierung von antiprionwirkstoffen mittels screening mit hohem durchsatz auf sift-basis - Google Patents

Identizifierung von antiprionwirkstoffen mittels screening mit hohem durchsatz auf sift-basis

Info

Publication number
ATE410696T1
ATE410696T1 AT05759896T AT05759896T ATE410696T1 AT E410696 T1 ATE410696 T1 AT E410696T1 AT 05759896 T AT05759896 T AT 05759896T AT 05759896 T AT05759896 T AT 05759896T AT E410696 T1 ATE410696 T1 AT E410696T1
Authority
AT
Austria
Prior art keywords
protein
aggregation
compound
antiprion
sift
Prior art date
Application number
AT05759896T
Other languages
English (en)
Inventor
Uwe Bertsch
Armin Giese
Hans Kretzschmar
Paul Tavan
Thomas Hirschberger
Jan Bieschke
Petra Weber
Konstanze Winklhofer
Joerg Tatzelt
F Hartl
Gerda Wuensch
Tobias Hoegen
Original Assignee
Univ Muenchen L Maximilians
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Muenchen L Maximilians filed Critical Univ Muenchen L Maximilians
Application granted granted Critical
Publication of ATE410696T1 publication Critical patent/ATE410696T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Neurosurgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
  • Information Retrieval, Db Structures And Fs Structures Therefor (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT05759896T 2004-05-24 2005-05-24 Identizifierung von antiprionwirkstoffen mittels screening mit hohem durchsatz auf sift-basis ATE410696T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP04012254 2004-05-24

Publications (1)

Publication Number Publication Date
ATE410696T1 true ATE410696T1 (de) 2008-10-15

Family

ID=35451505

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05759896T ATE410696T1 (de) 2004-05-24 2005-05-24 Identizifierung von antiprionwirkstoffen mittels screening mit hohem durchsatz auf sift-basis

Country Status (5)

Country Link
US (1) US20100029773A1 (de)
EP (1) EP1751553B1 (de)
AT (1) ATE410696T1 (de)
DE (1) DE602005010241D1 (de)
WO (1) WO2005116640A2 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE523788T1 (de) 2006-06-08 2011-09-15 Fu Berlin ASSAY ZUR DIAGNOSE VON ALZHEIMER BASIEREND AUF DER BESTIMMUNG DES VERHÄLTNISSES VON SEKRETASE-Aß-SPALTPRODUKTEN
WO2009009768A2 (en) * 2007-07-12 2009-01-15 Acumen Pharmaceuticals, Inc. METHODS OF INHIBITING THE FORMATION OF AMYLOID-β DIFFUSABLE LIGANDS USING A ACYLHYDRAZIDE COMPOUDS
US9006283B2 (en) 2007-07-12 2015-04-14 Acumen Pharmaceuticals, Inc. Methods of modifying amyloid β oligomers using non-peptidic compounds
RU2461377C2 (ru) * 2007-07-12 2012-09-20 Эйкьюмен Фамэсьютиклз, Инк. Способ улучшения когнитивной функции (варианты)
US8962677B2 (en) 2007-07-12 2015-02-24 Acumen Pharmaceuticals, Inc. Methods of restoring cognitive ability using non-peptidic compounds
CA2692775C (en) * 2007-07-12 2015-03-24 Acumen Pharmaceuticals, Inc. Methods of enhancing cognitive function using non-peptidic compounds
CA2692773A1 (en) * 2007-07-12 2009-01-15 Acumen Pharmaceuticals, Inc. Methods of modifying amyloid .beta. oligomers using non-peptidic compounds
WO2009079566A2 (en) 2007-12-18 2009-06-25 Acumen Pharmaceuticals, Inc. Novel addl receptor polypeptides, polynucleotides and host cells for recombinant production
KR101366372B1 (ko) 2012-01-30 2014-02-25 부산대학교 산학협력단 피부미백, 항산화 및 ｐｐａｒ 활성을 갖는 신규 화합물 및 이의 의학적 용도
GB201303507D0 (en) * 2013-02-27 2013-04-10 Hollfelder Florian Assays
WO2021225982A1 (en) * 2020-05-04 2021-11-11 Children's Hospital Medical Center Sos1 allosteric site targeting
US20220144758A1 (en) * 2020-11-12 2022-05-12 Oregon State University Molecular probe for selective detection of copper (ii) ions

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6613942B1 (en) * 1997-07-01 2003-09-02 Novo Nordisk A/S Glucagon antagonists/inverse agonists
WO2001025192A1 (en) * 1999-10-06 2001-04-12 Melacure Therapeutics Ab Guanidine derivatives and their use in the production of a medicament for blocking xanthine oxidase/dehydrogenase
US20050136444A1 (en) * 2003-09-25 2005-06-23 Scully Audra L. Treating neuropathic pain with neuropeptide FF receptor 2 agonists

Also Published As

Publication number Publication date
WO2005116640A2 (en) 2005-12-08
DE602005010241D1 (de) 2008-11-20
WO2005116640A3 (en) 2006-03-09
EP1751553A2 (de) 2007-02-14
EP1751553B1 (de) 2008-10-08
US20100029773A1 (en) 2010-02-04

Similar Documents

Publication Publication Date Title
ATE410696T1 (de) Identizifierung von antiprionwirkstoffen mittels screening mit hohem durchsatz auf sift-basis
Eaton Protein thiol oxidation in health and disease: techniques for measuring disulfides and related modifications in complex protein mixtures
WO2005005462A3 (en) Blys antagonists and uses thereof
ATE537448T1 (de) Nachweis von rho-proteinen
BRPI0812875A2 (pt) " método pra identificar se ou não um indivíduo está sob risco de desenvolvimento de sépsis severa, anticorpo específico para proteína ligante de heparina, método pra reduzir o risco de um indivíduo desenvolver sépsis severa, e, kit de teste ".
DE602004021185D1 (de) Auf bio-barcodes beruhender nachweis von zielanalyten
DE69939121D1 (de) Verfahren und materialien zum nachweis und zur messung von durch freie radikale verursachten schäden
HK1099810A1 (en) Methods, compositions and compound assays for inhibiting amyloid-beta protein production
JP2007082546A (ja) 毒性作用のマーカーとしてのｆａｂｐ４
ATE366420T1 (de) Kit und verfahren zur bestimmung von protein esm- 1
DK1565559T3 (da) Fluorescerende proteiner og chromoproteiner fra ikke aequorea hydrozoa arter samt fremgangsmåder til anvendelse deraf
ATE416259T1 (de) Fluoreszenzbasierende kinetische bestimmung der aktivität von transglutaminasen
DE60333486D1 (de) Fluoreszenzproteine aus copepoda-spezies und verfahren zur verwendung davon
DE602004023766D1 (de) Dot1-histon-methyltransferasen als ziel zur identifizierung von therapeutika gegen leukämie
ATE426168T1 (de) Verwendung von asc als marker fur kolorektalkarzinome
Seki et al. Establishment of a novel enzyme-linked immunosorbant assay for Thy-1; quantitative assessment of neuronal degeneration
US20070037143A1 (en) Method for screening for protease modulators
WO2005091199A3 (en) A method for identifying unknown proteins by a two-dimensional step and the use of markers
ATE534037T1 (de) Verwendung des proteins asc als marker für brustkrebs
DE602004005859D1 (de) Verwendung des proteins crabp ii (cellular retinoic acid-binding protein ii) als marker für brustkrebs
WO2006089801A8 (de) Verfahren zum redox-potential-abhängigen nachweis von targetmolekülen durch wechselwirkende polypeptide
WO2007095378A3 (en) Mass tagging for quantitative analysis of biomolecules using 13c labeled phenylisocyanate
Shimazaki et al. Isolation and analysis of amyloid-β 1-42 monomer and oligomers in liquid droplets using an immunoaffinity membrane
ATE455305T1 (de) Verfahren zur bestimmung des verhältnisses von zwei verschiedenen peptiden oder polynukleinsäuren
Laursen et al. Aging—the most important collagen neoepitope?

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties